Taiwo BO, et al. - In A5353, a phase 2, single-arm, pilot study, researchers examined once-daily dolutegravir (50 mg) plus lamivudine (300 mg) in treatment-naive participants with HIV-1 RNA ≥1000 and <500000 copies/mL. Study treatment was initiated in 120 participants (87% male, median age 30 years, 37 (31%) HIV-1 RNA >100000 copies/mL). Findings suggested dolutegravir plus lamivudine as efficacious in these individuals, however, development of resistance mutations was noted in 1 participant.